MICA: Understanding how bacteria respond to efflux inhibition
Lead Research Organisation:
University of Birmingham
Department Name: Institute of Microbiology and Infection
Abstract
The number of infections in people and animals caused by antibiotic resistant bacteria are increasing to alarming proportions around the world, and new treatments are urgently needed. However, historically, it has proven very difficult to find antibiotics that can get into bacteria such as E. coli (called Gram-negative bacteria). Even when they penetrate into the cell, most get pumped out/exported (called 'effluxed'). This export is via a biological 'vacuum cleaner' that sucks substances out of the inside to the outside of the bacterial cell. A single system can transport many different types of antibiotics. Without such systems Gram-negative bacteria are killed by very low concentrations of antibiotics. The combination of restricted entry of drugs into the bacterial cell (called outer membrane permeability) and export by multidrug resistance (MDR) efflux systems are why so many antibiotics that are effective treatments for infections caused by Gram positive bacteria, such as Staphylococcus aureus, do not work against Gram negative bacteria. Efflux systems that transport antibiotics out of the cell are not only required to give antibiotic resistance but without them bacteria are unable to cause an infection or form a biofilm - a community of bacteria that live on surfaces in the host and environment. Efflux inhibitors make the bacterium very sensitive to antibiotics, make them less able to colonise or infect their hosts and less able to form a biofilm. Therefore, efflux inhibitors offer the potential to increase the effectiveness of currently available and new drugs.
Our aim is to investigate the hypothesis that drug-resistant bacteria can emerge even in the presence of an efflux inhibitor. In this project, we will build upon our preliminary data by determining when E. coli becomes resistant to a combination of an antibiotic and efflux inhibitor. We will identify how the bacteria become drug resistant and find out if this type of resistance already exists in bacteria isolated from people and animals. Using a model that reproduces drug levels over time in people, we will identify ways to suppress the emergence of antibiotic and efflux inhibitor resistance.
To achieve the project aim, there are two applicants, a scientist and a doctor, plus three expert collaborators from the pharmaceutical industry and two universities. We will work together to provide new scientific information and knowledge crucial to the drug discovery of efflux inhibitors. Ultimately, this research will have a health benefit on the treatment of patients with life-threatening infections caused by antibiotic resistant bacteria.
Our aim is to investigate the hypothesis that drug-resistant bacteria can emerge even in the presence of an efflux inhibitor. In this project, we will build upon our preliminary data by determining when E. coli becomes resistant to a combination of an antibiotic and efflux inhibitor. We will identify how the bacteria become drug resistant and find out if this type of resistance already exists in bacteria isolated from people and animals. Using a model that reproduces drug levels over time in people, we will identify ways to suppress the emergence of antibiotic and efflux inhibitor resistance.
To achieve the project aim, there are two applicants, a scientist and a doctor, plus three expert collaborators from the pharmaceutical industry and two universities. We will work together to provide new scientific information and knowledge crucial to the drug discovery of efflux inhibitors. Ultimately, this research will have a health benefit on the treatment of patients with life-threatening infections caused by antibiotic resistant bacteria.
Technical Summary
Antibiotics are a cornerstone of modern medicine and used extensively by healthcare professionals. Therefore, antimicrobial resistance (AMR), especially by Gram-negative bacteria, poses a threat to human health. Furthermore, developing new antimicrobials has proved increasingly difficult over the past few decades. For Gram-negative bacteria this is due to combination of poor drug permeability coupled with active efflux. Therefore, one strategy to address the growing problem of AMR is to develop inhibitors of multidrug resistance (MDR) efflux pumps thereby sensitizing bacteria to already existing antimicrobials. Using efflux inhibitors in combination with antibiotics will increase and prolong their effectiveness.
This project will build upon our preliminary data that indicates that bacteria can become resistant to an efflux inhibitor alone and in combination with a fluoroquinolone antibiotic. In this project we will (1) investigate the bacterial response to efflux inhibition, (2) the conditions by which bacteria can evolve resistance, and (3) identify clinically relevant strategies to suppress resistance. We will do this using fluorescence based reporter systems that will detect transcription of RND MDR efflux pump and stress response genes in populations and single cells. We will use methods established in our laboratory including flow cytometry methods to (1) measure efflux activity in bacterial cells, and (2) sort populations of bacterial cells after exposure to drug +/- efflux inhibitor followed by whole genome sequencing. The mechanisms of resistance will be elucidated. We will also use established pharmacokinetic pharmacodynamic models to identify when resistance emerges and how it can be suppressed.
The work proposed in this project has significant implications for the treatment of bacterial infections.
This project will build upon our preliminary data that indicates that bacteria can become resistant to an efflux inhibitor alone and in combination with a fluoroquinolone antibiotic. In this project we will (1) investigate the bacterial response to efflux inhibition, (2) the conditions by which bacteria can evolve resistance, and (3) identify clinically relevant strategies to suppress resistance. We will do this using fluorescence based reporter systems that will detect transcription of RND MDR efflux pump and stress response genes in populations and single cells. We will use methods established in our laboratory including flow cytometry methods to (1) measure efflux activity in bacterial cells, and (2) sort populations of bacterial cells after exposure to drug +/- efflux inhibitor followed by whole genome sequencing. The mechanisms of resistance will be elucidated. We will also use established pharmacokinetic pharmacodynamic models to identify when resistance emerges and how it can be suppressed.
The work proposed in this project has significant implications for the treatment of bacterial infections.
Planned Impact
There will be numerous beneficiaries of the programme of research, which will lead to academic, economic and social impact. These include
- The academic research community through research outputs and scientific publications generated by the applicants, researchers and project partners.
- The researchers, who will be provided with an excellent platform for pursuing successful careers, which in the long-term will contribute to the scientific advancement and economic prosperity of the UK. They will also be provided with a unique opportunity to work with project partners in their laboratories.
- The MRC and RCUK in general, by adding to the UK's capacity and research strength in antibiotic resistance and drug discovery research.
- Industry (small medium enterprises and the pharmaceutical industry), who will have the opportunity to build upon new and novel data about efflux inhibitors for antibacterial drug discovery as a basis for new treatments to address serious infection challenges.
- The public, though a programme of dissemination and engagement activities, will be told about our discoveries, which could impact on their health and wellbeing. Information about antibiotics has appeal and interest to a broad lay audience.
- Developing countries through established collaborations of the applicants with researchers in Africa and China in relation to mechanisms of antibiotic resistance and impact of resistance upon infection and treatment.
- Government departments including the Department of Health and Public Health England as well as NHS Trusts, who can use the knowledge gained about multi-drug efflux to help formulate evidence based policy in relation to national and global infection challenges.
This project will benefit the academic community by providing new scientific information about efflux inhibitors as well as resistance development and mechanisms. Therefore, data arising from our research will be of interest to several active academic research communities. They will be informed by presentations at national and international conferences, publication of data in international peer reviewed journals, and by researcher exchange. All staff engaged within the project will contribute to the generation and dissemination of academic outputs. This project presents an excellent opportunity for PDRFs to develop their careers within strong research teams located within institutions where PDRFs have been able, and mentored, to progress to independence, transitioning into PIs in their own right.
There is an urgent need for new antibiotics to treat Gram-negative bacterial infections. This project will provide new scientific data about antibiotic-efflux inhibitors. Thus our results will be directly applicable to the development of novel therapies providing commercial benefit; (1) resistance data will be crucial in helping to understand the mechanism of efflux and inform the design of inhibitors; (2) new understanding of the pharmacokinetics and pharmacodynamics of drug-inhibitor combinations will be obtained; and (3) strategies to suppress emergence of resistance to combinations will be proposed. Results will be shared with other commercial stakeholders by publication and conference presentations. Assisting the development of antibiotic-inhibitor combinations will increase the health and wealth of the UK population and economy.
- The academic research community through research outputs and scientific publications generated by the applicants, researchers and project partners.
- The researchers, who will be provided with an excellent platform for pursuing successful careers, which in the long-term will contribute to the scientific advancement and economic prosperity of the UK. They will also be provided with a unique opportunity to work with project partners in their laboratories.
- The MRC and RCUK in general, by adding to the UK's capacity and research strength in antibiotic resistance and drug discovery research.
- Industry (small medium enterprises and the pharmaceutical industry), who will have the opportunity to build upon new and novel data about efflux inhibitors for antibacterial drug discovery as a basis for new treatments to address serious infection challenges.
- The public, though a programme of dissemination and engagement activities, will be told about our discoveries, which could impact on their health and wellbeing. Information about antibiotics has appeal and interest to a broad lay audience.
- Developing countries through established collaborations of the applicants with researchers in Africa and China in relation to mechanisms of antibiotic resistance and impact of resistance upon infection and treatment.
- Government departments including the Department of Health and Public Health England as well as NHS Trusts, who can use the knowledge gained about multi-drug efflux to help formulate evidence based policy in relation to national and global infection challenges.
This project will benefit the academic community by providing new scientific information about efflux inhibitors as well as resistance development and mechanisms. Therefore, data arising from our research will be of interest to several active academic research communities. They will be informed by presentations at national and international conferences, publication of data in international peer reviewed journals, and by researcher exchange. All staff engaged within the project will contribute to the generation and dissemination of academic outputs. This project presents an excellent opportunity for PDRFs to develop their careers within strong research teams located within institutions where PDRFs have been able, and mentored, to progress to independence, transitioning into PIs in their own right.
There is an urgent need for new antibiotics to treat Gram-negative bacterial infections. This project will provide new scientific data about antibiotic-efflux inhibitors. Thus our results will be directly applicable to the development of novel therapies providing commercial benefit; (1) resistance data will be crucial in helping to understand the mechanism of efflux and inform the design of inhibitors; (2) new understanding of the pharmacokinetics and pharmacodynamics of drug-inhibitor combinations will be obtained; and (3) strategies to suppress emergence of resistance to combinations will be proposed. Results will be shared with other commercial stakeholders by publication and conference presentations. Assisting the development of antibiotic-inhibitor combinations will increase the health and wealth of the UK population and economy.
Organisations
- University of Birmingham (Lead Research Organisation)
- UNIVERSITY OF EDINBURGH (Collaboration)
- UiT The Arctic University of Norway (Collaboration)
- Microbiotix Ltd (Collaboration)
- Association of the British Pharmaceutical Industry (Collaboration)
- University of Bristol (Collaboration)
- UNIVERSITY OF EXETER (Collaboration)
- Microbiotix (United States) (Project Partner)
- University of Tromsø - The Arctic University of Norway (Project Partner)
- UNIVERSITY OF EXETER (Project Partner)
- Association of the British Pharmaceutical Industry (Project Partner)
Publications
Youlden GH
(2021)
Time dependent asymptotic analysis of the gene regulatory network of the AcrAB-TolC efflux pump system in gram-negative bacteria.
in Journal of mathematical biology
Reading E
(2020)
Perturbed structural dynamics underlie inhibition and altered efflux of the multidrug resistance pump AcrB.
in Nature communications
Piddock LJV
(2019)
The 2019 Garrod Lecture: MDR efflux in Gram-negative bacteria-how understanding resistance led to a new tool for drug discovery.
in The Journal of antimicrobial chemotherapy
Marshall RL
(2020)
New Multidrug Efflux Inhibitors for Gram-Negative Bacteria.
in mBio
Grimsey EM
(2020)
Overexpression of RamA, Which Regulates Production of the Multidrug Resistance Efflux Pump AcrAB-TolC, Increases Mutation Rate and Influences Drug Resistance Phenotype.
in Antimicrobial agents and chemotherapy
Grimsey EM
(2020)
Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.
in mBio
Gatermann S
(2022)
Expected phenotypes and expert rules are important complements to antimicrobial susceptibility testing.
in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Ciusa ML
(2022)
Absence, loss-of-function, or inhibition of Escherichia coli AcrB does not increase expression of other efflux pump genes supporting the discovery of AcrB inhibitors as antibiotic adjuvants.
in The Journal of antimicrobial chemotherapy
Description | Building an antibacterial drug development pipeline to tackle priority R&D needs (WHO) |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Creating a New Generation of Antibiotics, Chatham House (policy) |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Description | DriveAB |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | FEMS Working Group Policy & Business |
Geographic Reach | Europe |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | MRC Drug target and validation |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | ReAct Africa webinar 30 April 2020 |
Geographic Reach | Africa |
Policy Influence Type | Contribution to a national consultation/review |
Description | UK Innovate, AMR programme |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Description | Studies to understand the efflux biology of Pseudomonas aeruginosa MexCD-OprJ and export of antibiotics |
Amount | £521,000 (GBP) |
Organisation | F. Hoffmann-La Roche AG |
Sector | Private |
Country | Global |
Start | 12/2020 |
End | 03/2022 |
Description | Alasdair MacGowan |
Organisation | University of Bristol |
Department | Bristol Research Unit |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Provision of mutants, intellectual input and expertise. |
Collaborator Contribution | Performing experiments, intellectual input and expertise. |
Impact | - |
Start Year | 2017 |
Description | Bartlomiej Waclaw |
Organisation | University of Edinburgh |
Department | Centre for Synthetic and Systems Biology (SynthSys) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | To provide chemical compounds and bacterial strains. |
Collaborator Contribution | Carry out specific experiments. |
Impact | - |
Start Year | 2017 |
Description | Microbiotix Ltd |
Organisation | Microbiotix Ltd |
Country | United States |
Sector | Private |
PI Contribution | Expertise, intellectual input, experiments with compounds provided by collaborator |
Collaborator Contribution | Provision of compounds for investigation, expertise, intellectual input |
Impact | - |
Start Year | 2017 |
Description | Pia Abel Zur Wiesch |
Organisation | UiT The Arctic University of Norway |
Country | Norway |
Sector | Academic/University |
PI Contribution | Expertise, intellectual input, experimental data |
Collaborator Contribution | Expertise, intellectual input, experimental strategy |
Impact | - |
Start Year | 2017 |
Description | Rob Beardmore |
Organisation | University of Exeter |
Department | Biosciences |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Provision of data, intellectual input and expertise. |
Collaborator Contribution | Mathematical modelling |
Impact | - |
Start Year | 2017 |
Description | Virginia Acha |
Organisation | Association of the British Pharmaceutical Industry |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Expertise, intellectual input |
Collaborator Contribution | Facilitate communication of data with end users |
Impact | - |
Start Year | 2017 |
Description | CIDRAP podcast, Superbugs and You, AMR Podcast Series |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | CIDRAP Podcasts and Webinars This content series involves webinars and audio podcasts provided by our world-renowned ASP Advisory Committee members and other topic experts. Each focuses on a specific area of interest within the topics of antimicrobial resistance and antimicrobial stewardship. The live webinars provide an interactive opportunity to viewers, and the recorded audio podcasts include short question-and-answer sessions. |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.cidrap.umn.edu/asp/meet-the-experts#Superbugs |
Description | Conference Talks |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | 08/09/16 Microbiology Society AGM Microbiology Society, London Prize winner lecture From outreach to basic research - addressing the crisis of AMR 28/09/16 Resistance and You! PHE, University of Manchester Speaker All about antibiotics - how they have changed our world 28/09/16 Resistance and You! PHE, University of Manchester Panel Chair Antibiotics and You! 07/11/16 Chevening leadership Foundation: R&D policy and strategies for innovation Chevening Foundation, London Speaker An overview of AMR, the scale of the problem and possible solutions 16/11/16 Plugging the Antibiotics Gap: A Medicinal Chemist's Perspective Royal Pharmaceutical Society, Alderley park, Cheshire Plenary speaker The global challenge of antibacterial drug resistance: what can be done? 13/01/17 Early Discovery of new antibiotics EU JPI AMR, Paris Panel Chair Analysis of the current European level portfolio: how to synergize the approaches, how to progress for new strategies / optimize funding around discovery 07/02/17 SHAMROCK annual lecture University of Sheffield Speaker Multi drug efflux systems: from basic research to discovering efflux inhibitors 23/03/17 Post Graduate Symposium Key note speaker University of Warwick MDR efflux 08/06/17 Daresbury IBM laboratory, Warrington 21-23/06/17 Hannover key note lecture Molecular basis of antibiotic permeability in Gram Negative bacteria. 4-5/07/17 AMR Award Holders Meeting Poster Presentation. 17/05/17 Pint of Science, Birmingham. 08/04/17 Roche Seminar MDR efflux systems basic research and discovery of new inhibitors. 24/10/17 UBM society , University of Birmingham, Loss of function of MDR efflux systems confers loss of virulence. 24/11/17 University of Upsalla, Sweden, Antibiotic resistance and why it matters to you. 21-22nd March 2019 - Garrod Lecture at the BSAC Spring Conference 2019, International Convention Centre, Birmingham. |
Year(s) Of Engagement Activity | 2016,2017,2019 |
Description | Interview with Sara Reardon, The Moonshot catalog; saving Antibiotics |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The Moonshot Catalog is an on-line home for an engaging and uplifting series of articles about ambitious but doable science- and technology-anchored challenges whose realization would do a lot of good for a lot of people. The articles reach a world wide audience. |
Year(s) Of Engagement Activity | 2020 |
URL | https://medium.com/the-moonshot-catalog/saving-antibiotics-ee9a49a38d87 |
Description | Media actitivies |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Professor Laura Piddock gave interviews to local, national and international media (TV, Radio and print). In the last 12 months this has included: BBC Newsnight BBC Radio 4 Live interview with Channel 4 Sky News live interviews Numerous Interviews about teixobactin including The Jeremy Vine Show, BBC Radio 2 (Jan 2015) • Provided quote to The Independent (March 2015) • Provided quotes to The Times, The Telegraph and The Independent on 'AncientBiotics' (March 2015). • Letter to The Times,' Britain faces an 'antibiotic Armageddon' (April 2015) • Filming for Panorama (April 2015) • Interview with BBC Radio 4 'The Report' (April 2015) BBC R4 Today x3 Various TV interviews syndicated worldwide including to CNN. Global media coverage (quoted >200 times) following the WHO's report on 30 April 2014. Federation of Infection Societies annual meeting: interview for short film: What is the cost of not developing another antibacterial drug Numerous print and online media interviews including The Times, The Telegraph, The Daily Mail, The Daily Express, The Metro. Quotations have often been repeated in worldwide media including in USA print media. BBC Horizon (broadcast 22 May 2014) Swiss National Science Foundation (SNSF) National Research Programme (NRP) Steering Committee with the title "Antimicrobial Resistance: a one-health approach" Plenary lecture at the 'Stimulating Antimicrobial Innovation' one day meeting at the NHLI, Imperial College London on October 22nd 2015. This is being organised by the Academy of Pharmaceutical Sciences GB, through the focus group on Microbiology and Anti-infectives. Board of Examiners in Biochemistry and Biotechnology at Imperial College London, I am writing to invite you to join us as an External Examiner for our BSc courses commencing with the 2015/16 academic year Invitation to be a panellist at BioInfect 2015 Guest lecture on antibiotic resistance for a new course we are developing as part of the University of Glasgow online learning course. Plenary Lecture Invitation: Research Day-St George's University of London 2 Dec talk on the subject of 'The challenges of AMR' at the launch of our new EPSRC funded AMR 'Bridging the Gaps' launch event University of Loughborough 7 Dec Swedish Research Council review panel to evaluate applications for a Networking call to bring together researchers from Sweden and India on e-Science for Life Science and Antibiotic resistance in a 'One Health' perspective Science Foundation Ireland review panel, Dublin SFI Investigators Programme 25th and 26th of February 2016. European Science Foundation Invitation to join Review Panel on AXA postdoctoral fellowships 2016 meetings in Feb and May 2016 ZIBI Interdisciplinary Center for Infection Biology and Immunity Symposium Therapeutic Resistances in Infectious Disease - Status Quo and Future Challenges, Berlin (June 27/28, 2016 Science Representative of the Buckinghamshire Federation of Women's Institutes to warmly invite you to speak at our science Investigation and Discovery Day on 7 March, in Aylesbury Invitation to Convene and speak in symposium: 2016 ASM Microbe plenary session Plenary lecture on AMR at the IPS conference September 2016 'Turn your nose up' campaign with the Farms not Factories organisation Took part in a written panel interview which will appear in Future Medicinal Chemistry's upcoming New Frontiers in Antimicrobial Drug Discovery special issue • Interviewed by Bloomberg News, Australia • Invited to interview with The Naked Scientist Flix Interactive about a Wellcome Trust funded project on an antimicrobial resistance computer game • Release of BSAC policies on antimicrobial use in animals and humans (May). • Interviewed by The Atlantic on the O'Neill Report, LJVP, (May). • Interviewed by BBC Radio 4 Today programme (1:22), LJVP (May). • Interviewed by BBC2 Victoria Derbyshire programme (May). • Interviewed by BBC Radio 4 Today programme (2:25) LJVP, (May). • Interviewed by BBC World on superbugs, LJVP, (May). • Invited to interview by Good Morning Britain about the O'Neill Report, LJVP, (May) • Interviewed by Kevin Fong, National Geographic, LJVP (May). • Interviewed by Bang! Oxford University's Science Magazine, LJVP (May). • Interviewed by a 7th grader for a project on antibiotic resistance, LJVP (May). • Interviewed by the Daily Mail Good Health, LJVP (May). • Provided comment to Science Media Centre on colistin-resistant bacteria in US woman, LJVP (May). • Invited to attend the UK premier of the documentary "Clean Hands", 28th June, London, LJVP (May). • Invited to interview by The Los Angeles Times, LJVP (June). • BBC Radio 4 'In our Time' programme, Penicillin, 9th June 2016, LJVP (June). • Invited to interview by "Sputnik - Orbiting the World with George Galloway", LJVP (June) • Invited to write an article for The Conversation, LJVP (June). • Reviewed and edited the script for a cartoon series generated by the Dundee Design School, LJVP (June). • Invited to write an article for the Spanish newspaper 'El País, LJVP (June). • Provided a quote to the British Medical Journal for a feature on the impact of NICE sepsis guidance on antibiotic subscribing, LJVP (June). • Provided NICHE with Antibiotic Action posters. • Invited to join expert panel for Innovate UK and Department of Health Funding competition: antimicrobial resistance, 29th November (Oct) • Invited by the Food Standards Agency and the Universities of Southampton and Newcastle, to participate in a joint antimicrobial resistance workshop. (Oct) • Invited to give a plenary lecture on antimicrobial resistance at the St George's Annual Research Day. (Oct) • Interviewed by the Sunday Express. (Oct) • Interview with Strategy& for a 'State of the Nation report' into AMR research & development in the UK. (Oct) • Invited to provide quotes to the Bureau of Investigative Journalism on the topic of antimicrobial resistance. (Oct) • Attended the 75th anniversary of penicillin, 7 November, University of Oxford. (LJVP) • Invited to appear and provide expertise in a BBC4 documentary with Michael Moseley • Supplement in the Guardian (Media Planet) under the One Health Agenda • Twitter: True Stories on video joint release with PHE (stories embargoed by PHE plus BBC Radio 4 stories and Tony Maxwell videos • Interview with Good Housekeeping magazine for WAAW • Invited to provide a comment on 'everyday germs in the home, their effects and how you can reduce the risk of illness' for a campaign run by Domestic Innovations. (July) • Working with BBC Five Live on concerns in relation to availability of antibiotics via online pharmacies. • Invited to provide comment for a story the Guardian are covering that looks at an antibiotic that kills Staphylococcus aureus. (July) • Invited to interview with TIME magazine about the anthrax outbreak in Russia • To provide expertise on a script for a feature film under development by Neon Films • To provide a quote for the cover of a forthcoming science book by the Royal Society of Chemistry 'The Microbes Fight Back: Antibiotic Resistance' • Interviewed by James Gallagher, BBC Health website - UN Resolution. (Sept) • Interview with BBC Radio 5 Live Drive - UN Resolution. (Sept) • Interviewed with Deutsche Welle Television, Berlin - UN Resolution. (Sept) • Interviewed by The Lancet Infectious Disease on UN Resolution to be published in November. (Sept) • Interview with BBC World Service - The Inquiry to discuss the antibiotics crisis, following the recent UN meeting. • Interview with BBC News - UN Resolution. (Sept). • BBC News filming for Antibiotic Awareness Week (Oct 2018). Promotion of Antibiotic Action (AA) being led by Prof. Laura Piddock. Antibiotic Action is a global initiative by the British Society for Antimicrobial Chemotherapy (BSAC) to highlight the threat to world health from multi-drug resistant bacteria and lobby for urgent action to develop new antimicrobial treatments |
Year(s) Of Engagement Activity | 2011,2012,2013,2014,2015,2016,2017,2018,2019 |
Description | Microbiology Society MicrobeTalk podcast 'A sustainable future and antimicrobial resistance' |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The Microbiology Society has a podcast called Microbe Talk, which includes interviews with researchers working in the field of microbiology.As part of 'A Sustainable Future' policy project, the Microbiology Society's policy team have produced three special episodes of Microbe Talk to explore the role of microbiology to address some of the world's biggest challenges. This episode, Emily speaks with Professor Laura Piddock from the University of Birmingham, who is currently on secondment as the Director of Scientific Affairs, Global Antibiotic Research and Development Partnership. Available to all online. |
Year(s) Of Engagement Activity | 2020 |
URL | https://soundcloud.com/microbiosoc/a-sustainable-future-and-antimicrobial-resistance |